A daily shot made everyday tasks a bit easier in a muscle disease, trial finds

Most people never think about the work it takes to chew a meal, hold up their head or finish a sentence. For people with generalised myasthenia gravis, those small jobs can tire the muscles fast and without warning. Eyelids droop, swallowing becomes hard work, and even breathing can be affected [1].

In a 12 week trial of 174 adults with the disease, a shot given once a day under the skin lowered a score of everyday trouble by 4.39 points. People on a look alike shot with no medicine in it, called a placebo, also improved, by 2.30 points. The gap between the two groups was 2.09 points [1].

One thing is worth saying early. Nobody has yet tested this shot side by side with the other new medicines for the disease, so nobody can say which works better [1][3].

The shot is called zilucoplan. The trial, known as RAISE, was led by James Howard of the University of North Carolina at Chapel Hill. It was published in the journal Lancet Neurology in 2023. The drug company UCB Pharma, which makes the shot, paid for it [1].

What goes wrong in the disease? It is autoimmune, which means the body's defense system, the immune system, attacks the body itself. Here it makes antibodies, proteins that mark things for attack, against the spots where nerves pass signals to muscles. Everyone in this trial had antibodies against the acetylcholine receptor, a kind of switch on the muscle that catches the nerve's signal [1].

The immune system also has a chain of proteins, called complement, that it uses to attack cells it has marked. The medicine blocks one step in that chain, called complement component 5, to stop the damage where nerves meet muscles. The medicine is a peptide, a short chain of the small building blocks of proteins, with its ends joined into a ring. The ring helps it last longer in the body [1][3].

How was the trial run?

The trial ran at 75 sites across Europe, Japan and North America. Chance decided, like a coin flip, who got what: 86 people got the medicine and 88 got the placebo. Neither the patients nor the doctors knew who got which. Nobody with only a mild case could join, because everyone needed a certain amount of trouble on two standard tests [1].

The main measure was an eight question survey called the Myasthenia Gravis Activities of Daily Living score. It asks about things like talking, chewing, breathing and holding the head up, and a lower score means less trouble. Patients fill it in themselves. That records what a person really feels, but it only works well if nobody knows which group they are in [1].

By week 12, scores had fallen by 4.39 points on the medicine and by 2.30 points on the placebo. The math showed that the gap of 2.09 points was very unlikely to be luck. The researchers summed it up this way [1]:

Zilucoplan treatment showed rapid and clinically meaningful improvements in myasthenia gravis-specific efficacy outcomes, had a favourable safety profile, and was well tolerated, with no major safety findings.

Howard and colleagues, Lancet Neurology, 2023 [1]

In plain words, the team says the shot helped quickly, by an amount that matters to patients, and that most people handled it well. Now look again at the second number. People on the placebo got better by more than two points with no medicine at all. In trials like this, scores move a lot even before any medicine counts [1].

Side effects were common in both groups: about three in four people on the medicine had one, and 70 in every 100 on the placebo. The most common was bruising where the shot went in. One person died in each group, and neither death was judged to be caused by the study drug [1].

What happened after 12 weeks? People who finished the trial could join a follow on study, called RAISE-XT, in which everyone got the medicine and everyone knew it. An early report on 200 patients said the gain held up to week 60 [2].

A study like that can show safety over a longer time, but it cannot prove the medicine helps. There is no group to compare with, everyone knows what they are getting, and only people who finished the first trial joined. In it, 94 in every 100 patients had some side effect. The most common was the disease itself getting worse, in about one in four [2].

A 2025 look inside the trial found that 54 people who had not yet had certain stronger treatments did about as well as the rest. But 54 people, split between medicine and placebo, is too few to settle when treatment should start [4].

What is missing from the record?

Several new medicines for this disease, working in different ways, were approved within a few years of each other. None has been tested against another in a trial where chance picks who gets what. Every comparison so far lines up separate trials, with different patients and different rules for joining [1][3].

Japan, the United States and the European Union all approved the shot in late 2023 [3].

So what does this work show? Over 12 weeks, in 174 adults, a daily shot lowered a score of everyday trouble by about two points more than a fake shot did. It does not show how the shot compares with the other medicines, or how people do over many years. Answering that would take side by side trials, longer studies, and a score that does not depend on people guessing their group [1][2][4].